Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.0252W HIGH $6.30
Volume
388.39 K
Value Traded
609.18 K
Short % Float
6.51%
Days to Cover
11.3
-8.09%Week
-20.1%1 Month
-8.09%3 Month
-60.25%6 Month
-66.98%5 Year
-66.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
170.96 M
EPS (TTM)
-0.40
P/E Ratio
-
Ent. Value
156.47 M
Total Shares
107.52 M
Float Shares
89.59 M
Insiders
16.68%
Institutions
11.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NGEN Catalyst Timeline
Dated clinical, regulatory and corporate events for NervGen Pharma Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NervGen Pharma Corp.
54Total events
7Upcoming
4Tier-1 (high impact)
2025 to 2028Coverage
Upcoming catalysts 2
Event history 39
▲First Patient DosedNVG-291Trial
First participant dosed in Phase 3 RESTORE study of NVG-291 in chronic cervical motor-incomplete SCI
chronic cervical motor-incomplete spinal cord injurysource ↗
●Quarterly UpdateCorporate
Restatement of audited FY2025 and unaudited Q2 2026 financial statements announced
◆ATM ProgramCorporate
Established at-the-market (ATM) facility with Leerink Partners on July 2, 2026
●Quarterly UpdateCorporate
NervGen remains on track to report third quarter 2026 financial results
◆Trial InitiationNVG-291Trial
Initiation of RESTORE registrational study in chronic tetraplegia
chronic tetraplegiasource ↗
◆Timing GuidanceNVG-291Presentation
Indication prioritization framework expected in mid-2026
neurotraumatic and neurologic conditionssource ↗
▲Full ResultsNVG-291Clinical Data
Positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery
chronic tetraplegiasource ↗
▼Equity OfferingCorporate
Pricing of US$60.0 million public offering of common shares and warrants
▲End Of Phase 2 MeetingNVG-291FDA Meeting
Completed successful FDA End-of-Phase 2 meeting for RESTORE study
chronic tetraplegiasource ↗
◆Oral PresentationPresentation
2026 Bloom Burton & Co. Healthcare Investor Conference Corporate Presentation
▲End Of Phase 2 MeetingNVG-291FDA Meeting
Successful End-of-Phase 2 meeting with FDA and alignment on RESTORE Phase 3 registrational study design
chronic tetraplegiasource ↗
●Enrollment CompleteNVG-291Trial
Elected to conclude enrollment in subacute tetraplegia cohort of CONNECT SCI study
subacute tetraplegiasource ↗
◆Trial InitiationNVG-291Trial
RESTORE Phase 3 registrational study initiation on-track for mid-2026
chronic tetraplegiasource ↗
▲End Of Phase 2 MeetingNVG-291FDA Meeting
Successful End-of-Phase 2 meeting with FDA and alignment on RESTORE registrational study
chronic tetraplegiasource ↗
◆Additional DataNVG-291Clinical Data
Biomechanical gait analyses results anticipated in 2Q 2026
spinal cord injurysource ↗
◆Timing GuidanceNVG-291Presentation
Update on status of CONNECT SCI subacute tetraplegia study in 2Q 2026
subacute tetraplegiasource ↗
◆Oral PresentationNVG-291Presentation
Present clinical data from biomechanical gait analyses of CONNECT SCI study in 2Q 2026
chronic tetraplegiasource ↗
▲FDA Feedback ReceivedNVG-291FDA Meeting
Achieved alignment with FDA on RESTORE clinical trial design
chronic spinal cord injurysource ↗
◆End Of Phase 2 MeetingNVG-291FDA Meeting
Completed End-of-Phase 2 meeting with FDA
chronic tetraplegiasource ↗
●Quarterly UpdateCorporate
Issuance of 245 common shares under ATM Program from Jan 1 to Mar 12, 2026
◆Oral PresentationPresentation
Leerink Partners Global Healthcare Conference 1x1 investor meetings
◆Management ChangeCorporate
Appointment of Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
◆Oral PresentationPresentation
TD Cowen 46th Annual Health Care Conference corporate presentation
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference corporate presentation
◆Oral PresentationPresentation
NervGen presents at Unite2Fight Paralysis 20th Annual Science and Advocacy Symposium
spinal cord injurysource ↗
▲Full ResultsNVG-291Clinical Data
Additional analyses reported in November 2025 supporting biological basis
chronic tetraplegiasource ↗
▲FDA Feedback ReceivedNVG-291FDA Meeting
Type C Meeting with FDA in September 2025
chronic tetraplegiasource ↗
▲Topline ReadoutNVG-291Clinical Data
Positive topline results from CONNECT SCI study
chronic tetraplegiasource ↗
Past FDA Catalysts and PDUFA Decisions
How NGEN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | NVG-291 | Phase 1b/2a data presentation | Phase 1b/2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 63%
Micro Cap(rank 414 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVG-291 Small moleculeNCT07799532 | Chronic Spinal Cord Injury | Phase 3 | RECRUITING | 150 | Dec 14, 2027 | ||||||
| NVG-291 Small moleculeCompletedNCT05308953 | Spinal Cord Injury | Phase 1 | COMPLETED | 74 | Jul 3, 2023 | ||||||
| NVG-291 Small moleculeCompletedNCT05965700 | Spinal Cord Injuries | Phase 1 | COMPLETED | 24 | Jan 21, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every NGEN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NVG-291 Fast TrackOrphan | chronic tetraplegia | Phase 1b/2a | 2026-05-26 | p=0.0197; 100% (10/10) of NVG-291 subjects were classified as responders; 10% (1/10) of placebo subjects (p=0.0001)Read More | NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI StudyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NGEN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 0.4 % | 2.16 M | 1.05 M |
NGEN Institutional Ownership Trends
NGEN Short Interest
Shares sold short, counted twice a month.
6.51%
Short % of Float
of tradable shares sold short
5.8M
Shares Sold Short
+6.2% vs prior count
11.3 Very high
Days to Cover
trading days of normal volume to buy every short share back
516.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NGEN ranks across every disease it competes in
Competitive Position is a premium feature
See how NGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNGEN News
NGENNervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury
NervGen has announced the dosing of the first participant in its Phase 3 RESTORE study, which evaluates NVG-291 for chronic cervical motor-incomplete spinal cord injury. This study follows positive results from the Phase 1b/2a CONNECT SCI study and aims to assess improvements in hand function and quality of life. Enrollment is expected to complete in late 2027, with topline data anticipated in early 2028.
Read more →NGENNervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
NervGen (NASDAQ: NGEN) announced plans to restate its financial statements for the year ended December 31, 2025, and the quarter ended June 30, 2026. The restatement will adjust the valuation of warrants and options, reducing stock-based compensation expenses and liabilities. Importantly, these adjustments are non-cash and will not impact the company's cash flow or operations.
Read more →NGENNervGen to Host Inaugural R&D Day on September 30, 2026
NervGen will host its inaugural R&D Day on September 30, 2026, focusing on the NVG-291 program. The event will feature presentations from leading experts in spinal cord injury care and will review clinical data and the Phase 3 RESTORE study design. A live Q&A session will follow the presentations, offering insights into the therapeutic potential of NVG-291.
Read more →NGENNervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
NervGen reported its Q2 2026 financial results, highlighting the upcoming Phase 3 RESTORE study for NVG-291 in chronic spinal cord injury (SCI) patients. The company has appointed new leadership and has sufficient cash reserves to support operations until 2028. Positive gait analysis results bolster confidence in the treatment's potential, despite a reported net loss of C$29.2 million.
Read more →NGENNervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
NervGen Pharma announced positive results from the Phase 1b/2a CONNECT SCI study, showing that NVG-291 significantly improves gait quality and promotes genuine neural recovery in chronic tetraplegia. The study found that all subjects receiving NVG-291 responded positively, contrasting sharply with placebo results. These findings support NVG-291's potential as a first-in-class therapy for spinal cord injury.
Read more →NGEN▼ -43.5%on this newsshared move
NervGen Announces Proposed Public Offering of Securities
NervGen Pharma Corp. has announced a public offering of common shares and warrants to fund the clinical advancement of its lead therapeutic candidate, NVG-291. The offering is subject to customary closing conditions and will utilize proceeds for clinical studies and corporate purposes. Leerink Partners and TD Cowen are managing the offering, which complies with relevant securities regulations.
Read more →NGEN▼ -43.5%on this newsshared move
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
NervGen Pharma Corp. has announced a public offering of 24 million common shares priced at $2.50 each, aiming to raise approximately $60 million. The proceeds will be used to advance its lead therapeutic candidate, NVG-291, through clinical studies. The offering is set to close on May 26, 2026, pending customary conditions.
Read more →NGENFORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company NervGen Pharma Corp. (" NervGen " or the " Company ") 112-970 Burrard Street Unit 1290 Vancouver, BC V6Z 2R4 Item 2: Date of Material Change
NervGen Pharma Corp. has announced a public offering of 24 million common shares at $2.50 each, aiming to raise about $60 million for clinical studies on NVG-291 and general corporate expenses. The offering includes warrants for additional shares at an exercise price of $3.68. PFP Biosciences, a company insider, participated in this offering, reflecting a supportive investment stance. The board approved the offering without material dissent, aiming for an expedited closing for business reasons.
Read more →NGENNervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Corp. reported its Q1 2026 financial results, highlighting a successful FDA End-of-Phase 2 meeting for its RESTORE study of NVG-291 in chronic tetraplegia. With site activation underway, the study is set to begin in mid-2026. The company also announced leadership changes to bolster its clinical development efforts and reported a net loss of $1.7 million for the quarter.
Read more →NGENCondensed consolidated interim financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars - Unaudited) For the three months ended
NervGen Pharma Corp. released its condensed consolidated interim financial statements for the three months ending March 31, 2026, which show a net loss of $1,675,549. This marks an improvement compared to a loss of $3,948,192 for the same period last year. The company remains in a pre-revenue stage, relying on financing to support its ongoing research and development efforts. Its overall financial position has weakened with a decrease in cash reserves and continued operational losses. The need for additional funding to progress clinical programs remains a significant concern.
Read more →NGENNervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
NervGen Pharma has appointed Dr. Keith Vendola as Chief Financial Officer to enhance its financial strategy and operations. Dr. Vendola brings over two decades of experience in biopharmaceutical finance and strategy. His leadership is expected to support the company's advancement of NVG-291, a potential first-in-class treatment for spinal cord injury.
Read more →NGENNervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
NervGen Pharma Corp. announced its participation in the H.C. Wainwright 'HCW@Home' series and the 2026 Bloom Burton & Co. Healthcare Investor Conference. CEO Adam Rogers and the executive team will represent the company at these events. NervGen is focused on developing neuroreparative therapeutics, particularly for spinal cord injuries, with its lead candidate NVG-291 showing promising results.
Read more →NGEN▼ -9.6%on this news
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
NervGen Pharma has successfully completed an End-of-Phase 2 meeting with the FDA, aligning on the parameters for its upcoming Phase 3 study, RESTORE, which will evaluate NVG-291 for chronic tetraplegia. The study aims to assess improvements in fine-motor hand use and includes various secondary endpoints. Initiation of RESTORE is on track for mid-2026.
Read more →NGENNervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
NervGen Pharma reported its full year 2025 financial results, highlighting significant progress in the development of NVG-291 for chronic tetraplegia. The company completed its End-of-Phase 2 meeting with the FDA and anticipates initiating a Phase 3 study in mid-2026. Additionally, positive results from the CONNECT SCI study were reported, supporting the therapeutic potential of NVG-291. The company plans to expand its clinical indications for NVG-291, with updates expected in mid-2026.
Read more →NGEN▼ -7%on this news
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
NervGen Pharma has announced its voluntary delisting from the TSX Venture Exchange, effective March 16, 2026. This move is aimed at reducing costs and administrative burdens as the company progresses into late-stage development for its lead candidate, NVG-291. Shareholders will continue to trade on Nasdaq without needing to take any action.
Read more →NGENForm 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer NervGen Pharma Corp. (" NervGen " or the " Company ") 112-970 Burrard Street, Unit 1290 Vancouver, BC V6Z 2R4 Item 2. Date of Material Cha
NervGen Pharma Corp. announced its decision to voluntarily delist its common shares from the TSX Venture Exchange, effective March 16, 2026. This move aims to reduce costs and administrative burdens, facilitating greater focus on clinical execution and shareholder value creation. Despite the delisting, shareholders will retain trading access on Nasdaq, and the company remains a reporting issuer under Canadian securities laws.
Read more →NGEN▲ +8.1%on this news
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
NervGen Pharma has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior VP of Patient Advocacy and Clinical Affairs. These appointments aim to strengthen the company's leadership as it advances NVG-291, a potential treatment for spinal cord injury. Both leaders bring extensive experience in regulatory affairs and patient advocacy, respectively.
Read more →NGENNervGen Pharma to Participate at Upcoming Investor Conferences
NervGen Pharma Corp. announced its participation in several upcoming investor conferences, including the Oppenheimer Healthcare Conference and the TD Cowen Health Care Conference. The company is focused on developing neuroreparative therapeutics for spinal cord injuries, with its lead candidate, NVG-291, showing promising results in clinical trials. The company aims to transform treatments for neurotraumatic conditions.
Read more →NGENNervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
NervGen Pharma announced the retirement of CFO Bill Adams, effective March 15, 2026. Adams will assist in the transition and has been instrumental in the company's growth, particularly in advancing their lead therapeutic candidate, NVG-291. The company is currently preparing for a Phase 3 clinical trial and continues to develop innovative neuroreparative therapeutics.
Read more →NGENNervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
NervGen Pharma Corp. will present at the Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium from February 15-17, 2026, in Washington, DC. The symposium aims to unite the spinal cord injury community and discuss advancements in research and treatment. NervGen's lead therapeutic candidate, NVG-291, has demonstrated durable improvements in patients with chronic spinal cord injury.
Read more →About NervGen Pharma Corp.
BIOPHARMAWATCH ELITE PLUS
Trade the next NGEN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime